The DOI matches its Crossref record; 238 of the 238 references it cites were found in a registry or an index.
Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options
Open accessAbstract
Epilepsy is a chronic neurologic disorder that affects over 70 million people worldwide. Despite the availability of over 20 antiseizure drugs (ASDs) for symptomatic treatment of epileptic seizures, about one-third of patients with epilepsy have seizures refractory to pharmacotherapy. Patients with such drug-resistant epilepsy (DRE) have increased risks of premature death, injuries, psychosocial dysfunction, and a reduced quality of life, so development of more effective therapies is an urgent clinical need. However, the various types of epilepsy and seizures and the complex temporal patterns of refractoriness complicate the issue. Furthermore, the underlying mechanisms of DRE are not fully understood, though recent work has begun to shape our understanding more clearly. Experimental models of DRE offer opportunities to discover, characterize, and challenge putative mechanisms of drug resistance. Furthermore, such preclinical models are important in developing therapies that may overcome drug resistance. Here, we will review the current understanding of the molecular, genetic, and structural mechanisms of ASD resistance and discuss how to overcome this problem. Encouragingly, better elucidation of the pathophysiological mechanisms underpinning epilepsies and drug resistance by concerted preclinical and clinical efforts have recently enabled a revised approach to the development of more promising therapies, including numerous potential etiology-specific drugs ("precision medicine") for severe pediatric (monogenetic) epilepsies and novel multitargeted ASDs for acquired partial epilepsies, suggesting that the long hoped-for breakthrough in therapy for as-yet ASD-resistant patients is a feasible goal. SIGNIFICANCE STATEMENT: Drug resistance provides a major challenge in epilepsy management. Here, we will review the current understanding of the molecular, genetic, and structural mechanisms of drug resistance in epilepsy and discuss how the problem might be overcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kwan, P., Arzimanoglou, A., Berg, A. T., Brodie, M. J., Allen Hauser, W., Mathern, G., Moshé, S. L., Perucca, E., Wiebe, S., & French, J. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02397.x · Cited by 4,877
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Elmore, M. R. P., Najafi, A. R., Koike, M. A., Dagher, N. N., Spangenberg, E. E., Rice, R. A., Kitazawa, M., Matusow, B., Nguyen, H., West, B. L., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.040 · Cited by 1,968
Chen, Z., Brodie, M. J., Liew, D., & Kwan, P. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3949 · Cited by 1,514
The neurobiology of antiepileptic drugs
Rogawski, M. A., & Löscher, W. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1430 · Cited by 1,239
Self-citationThe Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet
Olson, C. A., Vuong, H. E., Yano, J. M., Liang, Q. Y., Nusbaum, D. J., & Hsiao, E. Y. (2018) · Cell · doi:10.1016/j.cell.2018.04.027 · Cited by 1,057
Kwan, P., Schachter, S. C., & Brodie, M. J. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004418 · Cited by 1,052
On the Origin of Interictal Activity in Human Temporal Lobe Epilepsy in Vitro
Cohen, I., Navarro, V., Clemenceau, S., Baulac, M., & Miles, R. (2002) · Science · doi:10.1126/science.1076510 · Cited by 1,001
Blood-brain barrier tight junction permeability and ischemic stroke
Sandoval, K. E., & Witt, K. A. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.08.005 · Cited by 964
Devinsky, O., Vezzani, A., O'Brien, T. J., Jette, N., Scheffer, I. E., de Curtis, M., & Perucca, P. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.24 · Cited by 959
Self-citationLöscher, W. (2011) · Seizure · doi:10.1016/j.seizure.2011.01.003 · Cited by 932
Self-citationBlood–brain barrier structure and function and the challenges for CNS drug delivery
Abbott, N. J. (2013) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-013-9608-0 · Cited by 909
Drug resistance in brain diseases and the role of drug efflux transporters
Löscher, W., & Potschka, H. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1728 · Cited by 900
Self-citationViviani, B., Bartesaghi, S., Gardoni, F., Vezzani, A., Behrens, M. M., Bartfai, T., Binaglia, M., Corsini, E., Di Luca, M., Galli, C. L., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-25-08692.2003 · Cited by 893
Self-citationNeuroinflammatory pathways as treatment targets and biomarkers in epilepsy
Vezzani, A., Balosso, S., & Ravizza, T. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0217-x · Cited by 893
Self-citationQuantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors
Uchida, Y., Ohtsuki, S., Katsukura, Y., Ikeda, C., Suzuki, T., Kamiie, J., & Terasaki, T. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07208.x · Cited by 881
Inflammatory Mediators and Modulation of Blood–Brain Barrier Permeability
Abbott, N. J. (2000) · Cellular and Molecular Neurobiology · doi:10.1023/a:1007074420772 · Cited by 803
Comorbidities of epilepsy: current concepts and future perspectives
Keezer, M. R., Sisodiya, S. M., & Sander, J. W. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00225-2 · Cited by 778
Self-citationBrooks-Kayal, A. R., Shumate, M. D., Jin, H., Rikhter, T. Y., & Coulter, D. A. (1998) · Nature Medicine · doi:10.1038/2661 · Cited by 745
New avenues for anti-epileptic drug discovery and development
Löscher, W., Klitgaard, H., Twyman, R. E., & Schmidt, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4126 · Cited by 675
Self-citationNeuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability
Vezzani, A., & Viviani, B. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.027 · Cited by 670
Self-citationNeuronal activity modifies the DNA methylation landscape in the adult brain
Guo, J. U., Ma, D. K., Mo, H., Ball, M. P., Jang, M.-H., Bonaguidi, M. A., Balazer, J. A., Eaves, H. L., Xie, B., Ford, E., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2900 · Cited by 669
Siddiqui, A., Kerb, R., Weale, M. E., Brinkmann, U., Smith, A., Goldstein, D. B., Wood, N. W., & Sisodiya, S. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021986 · Cited by 665
Self-citationArroyo, S., Rumià, J., Martínez, I., & Ribalta, T. (1998) · PubMed · Cited by 652
The GABA Excitatory/Inhibitory Shift in Brain Maturation and Neurological Disorders
Ben-Ari, Y., Khalilov, I., Kahle, K. T., & Cherubini, E. (2012) · The Neuroscientist · doi:10.1177/1073858412438697 · Cited by 621
The kainic acid model of temporal lobe epilepsy
Lévesque, M., & Avoli, M. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.10.011 · Cited by 614
Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy
Barton, M. E., Klein, B. D., Wolf, H. H., & Steve White, H. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(01)00302-3 · Cited by 613
Importance of P-glycoprotein at blood–tissue barriers
Fromm, M. F. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.06.002 · Cited by 592
Modern antiepileptic drug development has failed to deliver: Ways out of the current dilemma
Löscher, W., & Schmidt, D. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03024.x · Cited by 590
Self-citationThe epidemiology of drug‐resistant epilepsy: A systematic review and meta‐analysis
Kalilani, L., Sun, X., Pelgrims, B., Noack‐Rink, M., & Villanueva, V. (2018) · Epilepsia · doi:10.1111/epi.14596 · Cited by 587
Vezzani, A., Conti, M., De Luigi, A., Ravizza, T., Moneta, D., Marchesi, F., & De Simoni, M. G. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-05054.1999 · Cited by 584
Self-citationEngaging neuroscience to advance translational research in brain barrier biology
Neuwelt, E. A., Bauer, B., Fahlke, C., Fricker, G., Iadecola, C., Janigro, D., Leybaert, L., Molnár, Z., O'Donnell, M. E., Povlishock, J. T., et al. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2995 · Cited by 579
Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects
König, J., Müller, F., & Fromm, M. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007518 · Cited by 575
Models of Seizures and Epilepsy
(2006) · Elsevier eBooks · doi:10.1016/b978-0-12-088554-1.x5000-2 · Cited by 561
Naylor, D. E., Liu, H., & Wasterlain, C. G. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4944-04.2005 · Cited by 548
MDR1 Gene Expression in Brain of Patients with Medically Intractable Epilepsy
Tishler, D. M., Weinberg, K. I., Hinton, D. R., Barbaro, N., Annett, G. M., & Raffel, C. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb01657.x · Cited by 527
Predictors of pharmacoresistant epilepsy
Hitiris, N., Mohanraj, R., Norrie, J., Sills, G. J., & Brodie, M. J. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2007.06.003 · Cited by 527
Mechanisms of action of currently used antiseizure drugs
Sills, G. J., & Rogawski, M. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107966 · Cited by 489
Wang, J., Lin, Z.-J., Liu, L., Xu, H.-Q., Shi, Y.-W., Yi, Y.-H., He, N., & Liao, W.-P. (2017) · Seizure · doi:10.1016/j.seizure.2016.11.030 · Cited by 487
Drug Resistance in Epilepsy: Putative Neurobiologic and Clinical Mechanisms
Schmidt, D., & Löscher, W. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.54904.x · Cited by 482
Self-citationDrug-Resistant Epilepsy: Multiple Hypotheses, Few Answers
Tang, F., Hartz, A. M. S., & Bauer, B. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00301 · Cited by 482
Sisodiya, S. M., Lin, W. ‐., Harding, B. N., Squier, M. V., & Thom, M. (2002) · Brain · doi:10.1093/brain/awf002 · Cited by 479
Self-citationVezzani, A., Moneta, D., Conti, M., Richichi, C., Ravizza, T., De Luigi, A., De Simoni, M. G., Sperk, G., Andell-Jonsson, S., Lundkvist, J., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190206797 · Cited by 464
Self-citationAngiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy
Rigau, V., Morin, M., Rousset, M.-C., de Bock, F., Lebrun, A., Coubes, P., Picot, M.-C., Baldy-Moulinier, M., Bockaert, J., Crespel, A., et al. (2007) · Brain · doi:10.1093/brain/awm118 · Cited by 429
Environmental standardization: cure or cause of poor reproducibility in animal experiments?
Richter, S. H., Garner, J. P., & Würbel, H. (2009) · Nature Methods · doi:10.1038/nmeth.1312 · Cited by 422
Riban, V., Bouilleret, V., Pham-Lê, B. T., Fritschy, J.-M., Marescaux, C., & Depaulis, A. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00064-7 · Cited by 414
Role of Multidrug Transporters in Pharmacoresistance to Antiepileptic Drugs
Löscher, W., & Potschka, H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.7 · Cited by 409
Self-citationMolecular and cellular mechanisms of pharmacoresistance in epilepsy
Remy, S., & Beck, H. (2006) · Brain · doi:10.1093/brain/awh682 · Cited by 406
Roles of the cation–chloride cotransporters in neurological disease
Kahle, K. T., Staley, K. J., Nahed, B. V., Gamba, G., Hebert, S. C., Lifton, R. P., & Mount, D. B. (2008) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0883 · Cited by 404
Löscher, W. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2222-z · Cited by 367
Self-citationVezzani, A., Maroso, M., Balosso, S., Sanchez, M.-A., & Bartfai, T. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.03.018 · Cited by 362
Self-citationKrauss, G. L., Klein, P., Brandt, C., Lee, S. K., Milanov, I., Milovanovic, M., Steinhoff, B. J., & Kamin, M. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30399-0 · Cited by 342
Berendt, M., Farquhar, R. G., Mandigers, P. J. J., Pakozdy, A., Bhatti, S. F. M., De Risio, L., Fischer, A., Long, S., Matiasek, K., Muñana, K., et al. (2015) · BMC Veterinary Research · doi:10.1186/s12917-015-0461-2 · Cited by 337
Self-citationStatus Epilepticus Increases the Intracellular Accumulation of GABAA Receptors
Goodkin, H. P. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.0900-05.2005 · Cited by 336
Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet
Rogawski, M. A., Löscher, W., & Rho, J. M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a022780 · Cited by 336
Self-citationSelective Alterations in GABAAReceptor Subtypes in Human Temporal Lobe Epilepsy
Loup, F., Wieser, H.-G., Yonekawa, Y., Aguzzi, A., & Fritschy, J.-M. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-14-05401.2000 · Cited by 307
How long does it take for partial epilepsy to become intractable?
Berg, A. T., Langfitt, J., Shinnar, S., Vickrey, B. G., Sperling, M. R., Walczak, T., Bazil, C., Pacia, S. V., & Spencer, S. S. (2003) · Neurology · doi:10.1212/01.wnl.0000031792.89992.ec · Cited by 305
Microglia–blood vessel interactions: a double-edged sword in brain pathologies
Dudvarski Stankovic, N., Teodorczyk, M., Ploen, R., Zipp, F., & Schmidt, M. H. H. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1524-y · Cited by 301
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2004) · Epilepsy Research · doi:10.1016/j.eplepsyres.2004.07.010 · Cited by 300
Maroso, M., Balosso, S., Ravizza, T., Iori, V., Wright, C. I., French, J., & Vezzani, A. (2011) · Neurotherapeutics · doi:10.1007/s13311-011-0039-z · Cited by 297
Self-citationUltra-Rare Genetic Variation in the Epilepsies: A Whole-Exome Sequencing Study of 17,606 Individuals
Feng, Y.-C. A., Howrigan, D. P., Abbott, L. E., Tashman, K., Cerrato, F., Singh, T., Heyne, H., Byrnes, A., Churchhouse, C., Watts, N., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.05.020 · Cited by 297
Self-citationAntagonism of peripheral inflammation reduces the severity of status epilepticus
Marchi, N., Fan, Q., Ghosh, C., Fazio, V., Bertolini, F., Betto, G., Batra, A., Carlton, E., Najm, I., Granata, T., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.002 · Cited by 284
The clinical impact of pharmacogenetics on the treatment of epilepsy
Löscher, W., Klotz, U., Zimprich, F., & Schmidt, D. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2008.01716.x · Cited by 281
Self-citationWeissberg, I., Wood, L., Kamintsky, L., Vazquez, O., Milikovsky, D. Z., Alexander, A., Oppenheim, H., Ardizzone, C., Becker, A., Frigerio, F., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.02.029 · Cited by 281
Self-citationA novel mechanism underlying drug resistance in chronic epilepsy
Remy, S., Gabriel, S., Urban, B. W., Dietrich, D., Lehmann, T. N., Elger, C. E., Heinemann, U., & Beck, H. (2003) · Annals of Neurology · doi:10.1002/ana.10473 · Cited by 275
Löscher, W., Puskarjov, M., & Kaila, K. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.045 · Cited by 271
Self-citationLosartan prevents acquired epilepsy via TGF‐β signaling suppression
Bar‐Klein, G., Cacheaux, L. P., Kamintsky, L., Prager, O., Weissberg, I., Schoknecht, K., Cheng, P., Kim, S. Y., Wood, L., Heinemann, U., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24147 · Cited by 270
Bauer, B., Hartz, A. M. S., Pekcec, A., Toellner, K., Miller, D. S., & Potschka, H. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.041210 · Cited by 270
Self-citationFebrile infection‐related epilepsy syndrome treated with anakinra
Kenney‐Jung, D. L., Vezzani, A., Kahoud, R. J., LaFrance‐Corey, R. G., Ho, M., Muskardin, T. W., Wirrell, E. C., Howe, C. L., & Payne, E. T. (2016) · Annals of Neurology · doi:10.1002/ana.24806 · Cited by 265
Self-citationReproducibility of preclinical animal research improves with heterogeneity of study samples
Voelkl, B., Vogt, L., Sena, E. S., & Würbel, H. (2018) · PLOS Biology · doi:10.1371/journal.pbio.2003693 · Cited by 262
A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1
Balosso, S., Maroso, M., Sanchez-Alavez, M., Ravizza, T., Frasca, A., Bartfai, T., & Vezzani, A. (2008) · Brain · doi:10.1093/brain/awn271 · Cited by 260
Self-citationAnimal models in epilepsy research: legacies and new directions
Grone, B. P., & Baraban, S. C. (2015) · Nature Neuroscience · doi:10.1038/nn.3934 · Cited by 259
van Vliet, E. A., Aronica, E., Vezzani, A., & Ravizza, T. (2018) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12444 · Cited by 259
Self-citationManaging drug-resistant epilepsy: challenges and solutions
Dalic, L., & Cook, M. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s84852 · Cited by 258
Seizure-induced brain-borne inflammation sustains seizure recurrence and blood-brain barrier damage
Librizzi, L., Noè, F., Vezzani, A., de Curtis, M., & Ravizza, T. (2012) · Annals of Neurology · doi:10.1002/ana.23567 · Cited by 253
Self-citationAltered composition of the gut microbiome in patients with drug-resistant epilepsy
Peng, A., Qiu, X., Lai, W., Li, W., Zhang, L., Zhu, X., He, S., Duan, J., & Chen, L. (2018) · Epilepsy Research · doi:10.1016/j.eplepsyres.2018.09.013 · Cited by 247
Pressler, R. M., Boylan, G. B., Marlow, N., Blennow, M., Chiron, C., Cross, J. H., de Vries, L. S., Hallberg, B., Hellström-Westas, L., Jullien, V., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70303-5 · Cited by 244
Animal models of intractable epilepsy
Löscher, W. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00035-x · Cited by 244
Self-citationProgress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI)
Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2013) · Epilepsy Research · doi:10.1016/j.eplepsyres.2012.10.001 · Cited by 243
Rizzi, M., Caccia, S., Guiso, G., Richichi, C., Gorter, J. A., Aronica, E., Aliprandi, M., Bagnati, R., Fanelli, R., D'Incalci, M., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-14-05833.2002 · Cited by 243
Self-citationLöscher, W., & Schmidt, D. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00607.x · Cited by 239
Self-citationLazarowski, A., Czornyj, L., Lubienieki, F., Girardi, E., Vazquez, S., & D'Giano, C. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01302.x · Cited by 239
Potschka, H., Fedrowitz, M., & Löscher, W. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049858 · Cited by 234
Self-citationBlood–brain barrier dysfunction, seizures and epilepsy
van Vliet, E. A., Aronica, E., & Gorter, J. A. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.10.003 · Cited by 229
Löscher, W., & Friedman, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020591 · Cited by 229
Self-citationThe transport of antiepileptic drugs by P-glycoprotein
Zhang, C., Kwan, P., Zuo, Z., & Baum, L. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.003 · Cited by 225
Brandt, C., Bethmann, K., Gastens, A. M., & Löscher, W. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.06.014 · Cited by 221
Self-citationO'Brien, F. E., Dinan, T. G., Griffin, B. T., & Cryan, J. F. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01557.x · Cited by 215
Pharmacoresistance and the role of surgery in difficult to treat epilepsy
Wiebe, S., & Jette, N. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.181 · Cited by 207
Ferrari, C. C., Depino, A. M., Prada, F., Muraro, N., Campbell, S., Podhajcer, O., Perry, V. H., Anthony, D. C., & Pitossi, F. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63438-4 · Cited by 207
How theories evolved concerning the mechanism of action of barbiturates
Löscher, W., & Rogawski, M. A. (2012) · Epilepsia · doi:10.1111/epi.12025 · Cited by 207
Self-citationEstimating the Cost of Epilepsy in Europe: A Review with Economic Modeling
Pugliatti, M., Beghi, E., Forsgren, L., Ekman, M., & Sobocki, P. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01251.x · Cited by 197
Iori, V., Iyer, A. M., Ravizza, T., Beltrame, L., Paracchini, L., Marchini, S., Cerovic, M., Hill, C., Ferrari, M., Zucchetti, M., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.007 · Cited by 190
Self-citationRavizza, T., & Vezzani, A. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2005.07.063 · Cited by 189
Self-citationDrug development for refractory epilepsy: The past 25 years and beyond
Golyala, A., & Kwan, P. (2017) · Seizure · doi:10.1016/j.seizure.2016.11.022 · Cited by 188
Balestrini, S., & Sisodiya, S. M. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.01.014 · Cited by 186
Self-citationRoseti, C., van Vliet, E. A., Cifelli, P., Ruffolo, G., Baayen, J. C., Di Castro, M. A., Bertollini, C., Limatola, C., Aronica, E., Vezzani, A., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.07.003 · Cited by 181
Self-citationP-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study
Feldmann, M., Asselin, M.-C., Liu, J., Wang, S., McMahon, A., Anton-Rodriguez, J., Walker, M., Symms, M., Brown, G., Hinz, R., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70109-1 · Cited by 181
Self-citationMicrobiota-gut brain axis involvement in neuropsychiatric disorders
Iannone, L. F., Preda, A., Blottière, H. M., Clarke, G., Albani, D., Belcastro, V., Carotenuto, M., Cattaneo, A., Citraro, R., Ferraris, C., et al. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1638763 · Cited by 177
Self-citationMiller-Delaney, S. F. C., Bryan, K., Das, S., McKiernan, R. C., Bray, I. M., Reynolds, J. P., Gwinn, R., Stallings, R. L., & Henshall, D. C. (2015) · Brain · doi:10.1093/brain/awu373 · Cited by 171
Volk, H. A., & Löscher, W. (2005) · Brain · doi:10.1093/brain/awh437 · Cited by 170
Self-citationMechanisms of antiepileptic drug resistance
Sisodiya, S. M. (2003) · Current Opinion in Neurology · doi:10.1097/00019052-200304000-00013 · Cited by 164
Self-citationIntrinsic Severity as a Determinant of Antiepileptic Drug Refractoriness
Rogawski, M. A., & Johnson, M. R. (2008) · Epilepsy Currents · doi:10.1111/j.1535-7511.2008.00272.x · Cited by 164
Löscher, W. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.05.016 · Cited by 164
Self-citationEarly seizure frequency and aetiology predict long-term medical outcome in childhood-onset epilepsy
Sillanpaa, M., & Schmidt, D. (2008) · Brain · doi:10.1093/brain/awn357 · Cited by 163
ABC transporters at the blood–brain barrier
Mahringer, A., & Fricker, G. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1168804 · Cited by 163
Cucullo, L., Hossain, M., Rapp, E., Manders, T., Marchi, N., & Janigro, D. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2006.00960.x · Cited by 162
Kehne, J. H., Klein, B. D., Raeissi, S. D., & Sharma, S. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2275-z · Cited by 160
Morin-Brureau, M., Lebrun, A., Rousset, M.-C., Fagni, L., Bockaert, J., de Bock, F., & Lerner-Natoli, M. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.5692-10.2011 · Cited by 159
Malformations of Cortical Development and Epilepsy
Barkovich, A. J., Dobyns, W. B., & Guerrini, R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a022392 · Cited by 159
Hsiao, J. H., Yuan, T., Tsai, M. S., Lu, C., Lin, Y.-H., Lee, M. L., Lin, S., Chang, F., Pimentel, H. L., Olive, C., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.05.011 · Cited by 152
van Vliet, E. A., Zibell, G., Pekcec, A., Schlichtiger, J., Edelbroek, P. M., Holtman, L., Aronica, E., Gorter, J. A., & Potschka, H. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.09.012 · Cited by 149
Self-citationLöscher, W., Luna‐Tortós, C., Römermann, K., & Fedrowitz, M. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211797440212 · Cited by 149
Self-citationPharmacotherapeutic targeting of cation‐chloride cotransporters in neonatal seizures
Puskarjov, M., Kahle, K. T., Ruusuvuori, E., & Kaila, K. (2014) · Epilepsia · doi:10.1111/epi.12620 · Cited by 149
Bialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2020) · Epilepsia · doi:10.1111/epi.16725 · Cited by 149
Yang, G., Gong, C., Qin, Z., Liu, X., & Betz, A. L. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00007-8 · Cited by 148
Kim, S. Y., Senatorov, V. V., Morrissey, C. S., Lippmann, K., Vazquez, O. N., Milikovsky, D. Z., Gu, F., Parada, I., Prince, D. A., Becker, A. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-07394-3 · Cited by 148
Imaging blood–brain barrier dysfunction as a biomarker for epileptogenesis
Bar‐Klein, G., Lublinsky, S., Kamintsky, L., Noyman, I., Veksler, R., Dalipaj, H., Senatorov, V. V., Swissa, E., Rosenbach, D., Elazari, N., et al. (2017) · Brain · doi:10.1093/brain/awx073 · Cited by 147
Neuropathology of the blood–brain barrier and pharmaco-resistance in human epilepsy
Liu, J. Y. W., Thom, M., Catarino, C. B., Martinian, L., Figarella‐Branger, D., Bartoloméi, F., Koepp, M. J., & Sisodiya, S. M. (2012) · Brain · doi:10.1093/brain/aws147 · Cited by 144
Self-citationSaunders, N. R., Habgood, M. D., Møllgård, K., & Dziegielewska, K. M. (2016) · F1000Research · doi:10.12688/f1000research.7378.1 · Cited by 143
Coulter, D. A. (2001) · International review of neurobiology · doi:10.1016/s0074-7742(01)45013-6 · Cited by 139
Selective Na V 1.1 activation rescues Dravet syndrome mice from seizures and premature death
Richards, K., Milligan, C. J., Richardson, R. J., Jancovski, N., Grunnet, M., Jacobson, L. H., Undheim, E. A. B., Mobli, M., Chow, C. Y., Herzig, V., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1804764115 · Cited by 139
Galovic, M., Baudracco, I., Wright-Goff, E., Sulca, G. E. P., Nachev, P., Wandschneider, B., Woermann, F. G., Thompson, P. J., Baxendale, S., McEvoy, A. W., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0204 · Cited by 139
Self-citationBialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2018) · Epilepsia · doi:10.1111/epi.14557 · Cited by 136
Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition
Zibell, G., Unkrüer, B., Pekcec, A., Hartz, A. M. S., Bauer, B., Miller, D. S., & Potschka, H. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.01.009 · Cited by 134
Self-citationEllerkmann, R. K., Remy, S., Chen, J., Гарриевич, С. Д., Elger, C. E., Urban, B. W., Becker, A. J., & Beck, H. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00168-4 · Cited by 132
Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man
Matagne, A., & Klitgaard, H. (1998) · Epilepsy Research · doi:10.1016/s0920-1211(98)00016-3 · Cited by 127
Emerging roles for the intestinal microbiome in epilepsy
Lum, G. R., Olson, C. A., & Hsiao, E. Y. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104576 · Cited by 127
Dilena, R., Mauri, E., Aronica, E., Bernasconi, P., Bana, C., Cappelletti, C., Carrabba, G. G., Ferrero, S., Giorda, R., Guez, S., et al. (2019) · Epilepsia Open · doi:10.1002/epi4.12317 · Cited by 121
Self-citationFrigerio, F., Frasca, A., Weissberg, I., Parrella, S., Friedman, A., Vezzani, A., & Noè, F. M. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03666.x · Cited by 120
Self-citationA new hypothesis of drug refractory epilepsy: Neural network hypothesis
Fang, M., Xi, Z., Wu, Y. F., & Wang, X. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.02.039 · Cited by 118
Holtman, L., van Vliet, E. A., van Schaik, R., Queiroz, C. M., Aronica, E., & Gorter, J. A. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2008.12.006 · Cited by 117
van Vliet, E. A., van Schaik, R., Edelbroek, P. M., Voskuyl, R. A., Redeker, S., Aronica, E., Wadman, W. J., & Gorter, J. A. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.121178 · Cited by 117
Clarkson, B. D. S., LaFrance‐Corey, R. G., Kahoud, R. J., Farias‐Moeller, R., Payne, E. T., & Howe, C. L. (2019) · Annals of Neurology · doi:10.1002/ana.25439 · Cited by 117
Kobow, K., & Blümcke, I. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.01.012 · Cited by 116
Over-expression of Pglycoprotein in malformations of cortical development
Sisodiya, S. M., Heffernan, J. M., & Squier, M. V. (1999) · Neuroreport · doi:10.1097/00001756-199911080-00032 · Cited by 115
Self-citationModulating P‐glycoprotein regulation: Future perspectives for pharmacoresistant epilepsies?
Potschka, H. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02585.x · Cited by 111
Self-citationCost of refractory epilepsy in adults in the USA
Murray, M. I., Halpern, M. T., & Leppik, I. E. (1996) · Epilepsy Research · doi:10.1016/0920-1211(95)00090-9 · Cited by 111
Inflammation and Epilepsy: Preclinical Findings and Potential Clinical Translation
Terrone, G., Salamone, A., & Vezzani, A. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666170926113754 · Cited by 111
Self-citationThe intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs
Rogawski, M. A. (2013) · Epilepsia · doi:10.1111/epi.12182 · Cited by 110
Rowley, N. M., & White, H. S. (2010) · Epilepsy Research · doi:10.1016/j.eplepsyres.2010.09.002 · Cited by 109
Duveau, V., Pouyatos, B., Bressand, K., Bouyssières, C., Chabrol, T., Roche, Y., Depaulis, A., & Roucard, C. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12523 · Cited by 109
Benefit of combination therapy in epilepsy: A review of the preclinical evidence with levetiracetam
Kaminski, R. M., Matagne, A., Patsalos, P. N., & Klitgaard, H. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01713.x · Cited by 108
New Developments in Antiepileptic Drug Resistance: An Integrative View
Schmidt, D., & Löscher, W. (2009) · Epiliepsy currents/Epilepsy currents · doi:10.1111/j.1535-7511.2008.01289.x · Cited by 108
Self-citationPostma, T., Krupp, E., Li, X. L., Post, R. M., & Weiss, S. R. B. (2000) · Epilepsia · doi:10.1111/j.1499-1654.2000.001514.x · Cited by 107
Broekaart, D. W. M., Anink, J. J., Baayen, J. C., Idema, S., de Vries, H. E., Aronica, E., Gorter, J. A., & van Vliet, E. A. (2018) · Epilepsia · doi:10.1111/epi.14550 · Cited by 107
Löscher, W., Rundfeldt, C., & Hönack, D. (1993) · Epilepsy Research · doi:10.1016/0920-1211(93)90058-f · Cited by 106
Self-citationA systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target
Srivastava, P. K., van Eyll, J. M., Godard, P., Mazzuferi, M., Delahaye‐Duriez, A., Steenwinckel, J. V., Gressèns, P., Danis, B., Vandenplas, C., Foerch, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06008-4 · Cited by 106
Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade
DeSena, A. D., Do, T., & Schulert, G. S. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1063-2 · Cited by 105
Preclinical Animal Models for Dravet Syndrome: Seizure Phenotypes, Comorbidities and Drug Screening
Griffin, A., Hamling, K. R., Hong, S., Anvar, M., Lee, L. P., & Baraban, S. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00573 · Cited by 103
Targeting Prostaglandin E2 EP1 Receptors Prevents Seizure-Associated P-glycoprotein Up-Regulation
Pekcec, A., Unkrüer, B., Schlichtiger, J., Soerensen, J., Hartz, A. M. S., Bauer, B., van Vliet, E. A., Gorter, J. A., & Potschka, H. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.152520 · Cited by 99
Self-citationBlood–brain barrier dysfunction in status epileptics: Mechanisms and role in epileptogenesis
Swissa, E., Serlin, Y., Vazana, U., Prager, O., & Friedman, A. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.04.038 · Cited by 99
The methylation hypothesis of pharmacoresistance in epilepsy
Kobow, K., El‐Osta, A., & Blümcke, I. (2013) · Epilepsia · doi:10.1111/epi.12183 · Cited by 97
Marcon, J., Gagliardi, B., Balosso, S., Maroso, M., Noè, F. M., Morin‐Brureau, M., Lerner‐Natoli, M., Vezzani, A., & Ravizza, T. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.12.018 · Cited by 96
Self-citationGhosh, C., Puvenna, V., Gonzalez-Martinez, J. A., Janigro, D., & Marchi, N. (2011) · Current Drug Metabolism · doi:10.2174/138920011798357051 · Cited by 96
Römermann, K., Helmer, R., & Löscher, W. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.01.015 · Cited by 95
Self-citationBrandt, C., Volk, H. A., & Löscher, W. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.16904.x · Cited by 93
Self-citationFractalkine/CX 3 CL 1 modulates GABAA currents in human temporal lobe epilepsy
Roseti, C., Fucile, S., Lauro, C., Martinello, K., Bertollini, C., Esposito, V., Mascia, A., Catalano, M., Aronica, E., Limatola, C., et al. (2013) · Epilepsia · doi:10.1111/epi.12354 · Cited by 92
Klein, S., Bankstahl, M., & Löscher, W. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.11.008 · Cited by 92
Self-citationWilcox, K. S., West, P. J., & Metcalf, C. S. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107811 · Cited by 91
Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy
Schlichtiger, J., Pekcec, A., Bartmann, H., Winter, P., Fuest, C., Soerensen, J., & Potschka, H. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00765.x · Cited by 89
Self-citationTargeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug
Doeser, A., Dickhof, G., Reitze, M., et al. (2014) · Brain · doi:10.1093/brain/awu339 · Cited by 89
The NINDS Epilepsy Research Benchmarks
Kelley, M. S., Jacobs, M. P., Lowenstein, D. H., & Stewards, F. T. N. E. B. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2008.01813.x · Cited by 88
Pirker, S., Schwarzer, C., Czech, T., Baumgartner, C., Pockberger, H., Maier, H., Hauer, B., Sieghart, W., Fürtinger, S., & Sperk, G. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.8.820 · Cited by 85
Risks and predictive biomarkers of sudden unexpected death in epilepsy patient
Ryvlin, P., Rheims, S., & Lhatoo, S. D. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000668 · Cited by 85
Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy
Holtman, L., van Vliet, E. A., Edelbroek, P. M., Aronica, E., & Gorter, J. A. (2010) · Epilepsy Research · doi:10.1016/j.eplepsyres.2010.06.011 · Cited by 84
Development and pharmacologic characterization of the rat 6 Hz model of partial seizures
Metcalf, C. S., West, P. J., Thomson, K. E., Edwards, S. F., Smith, M. D., White, H. S., & Wilcox, K. S. (2017) · Epilepsia · doi:10.1111/epi.13764 · Cited by 84
Potschka, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.007 · Cited by 81
Self-citationBenzodiazepine‐refractory status epilepticus: pathophysiology and principles of treatment
Niquet, J., Baldwin, R. A., Suchomelová, L., Lumley, L. A., Naylor, D. E., Eavey, R., & Wasterlain, C. G. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13147 · Cited by 81
Chouchi, M., Kaabachi, W., Klaa, H., Tizaoui, K., Turki, I., & Hila, L. (2017) · BMC Neurology · doi:10.1186/s12883-017-0801-x · Cited by 81
Coulter, D. A. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb01565.x · Cited by 80
Drug Transporters in the Epileptic Brain
Löscher, W. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.00993.x · Cited by 79
Self-citationP-gp Protein Expression and Transport Activity in Rodent Seizure Models and Human Epilepsy
Hartz, A. M. S., Pekcec, A., Soldner, E. L. B., Zhong, Y., Schlichtiger, J., & Bauer, B. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00770 · Cited by 79
Rundfeldt, C., & Löscher, W. (2013) · CNS Drugs · doi:10.1007/s40263-013-0129-z · Cited by 77
Self-citationPharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats
Potschka, H., Volk, H. A., & Löscher, W. (2004) · Neuroreport · doi:10.1097/01.wnr.0000134840.10390.a4 · Cited by 75
Self-citationMantegazza, M., & Broccoli, V. (2019) · Epilepsia · doi:10.1111/epi.14700 · Cited by 75
Chung, F., Santiago, J. S., de Jesus, M., Trinidad, C. V., & See, M. E. (2016) · Europe PMC (PubMed Central) · Cited by 74
In search of models of pharmacoresistant epilepsy
Wahab, A., Albus, K., Gabriel, S., et al. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02632.x · Cited by 73
Blanco, M. M., Santos-Junior, J. G., Perez‐Mendes, P., Kohek, S. R. B., Cavarsan, C. F., Hummel, M., Albuquerque, C., & Mello, L. E. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01797.x · Cited by 73
Risk for injuries and accidents in epilepsy
Mahler, B., Carlsson, S., Andersson, T., & Tomson, T. (2018) · Neurology · doi:10.1212/wnl.0000000000005035 · Cited by 73
Galanopoulou, A. S., & Moshé, S. L. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.015 · Cited by 69
Carbamazepine-resistance in the epileptic dentate gyrus of human hippocampal slices
Jandová, K., Päsler, D., Antônio, L. L., Raue, C., Ji, S., Njunting, M., Kann, O., Kovacs, R., Meencke, H. J., Cavalheiro, É. A., et al. (2006) · Brain · doi:10.1093/brain/awl218 · Cited by 69
Overall and cause-specific premature mortality in epilepsy: A systematic review
Watila, M. M., Balarabe, S. A., Ojo, O., Keezer, M. R., & Sander, J. W. A. S. (2018) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.07.017 · Cited by 69
Weidner, L. D., Kannan, P., Mitsios, N., Kang, S. J., Hall, M. D., Theodore, W. H., Innis, R. B., & Mulder, J. (2018) · Epilepsia · doi:10.1111/epi.14505 · Cited by 68
Klément, W., Blaquière, M., Zub, E., de Bock, F., Boux, F., Barbier, E., Audinat, É., Lerner‐Natoli, M., & Marchi, N. (2019) · Epilepsia · doi:10.1111/epi.16019 · Cited by 66
Potschka, H., Fedrowitz, M., & Löscher, W. (2003) · Epilepsia · doi:10.1111/j.0013-9580.2003.22603.x · Cited by 63
Self-citationBlood–brain barrier dysfunction can contribute to pharmacoresistance of seizures
Salar, S., Maslarova, A., Lippmann, K., Herzig-Nichtweiß, J. F., Weissberg, I., Sheintuch, L., Kunz, W. S., Shorer, Z., Friedman, A., & Heinemann, U. (2014) · Epilepsia · doi:10.1111/epi.12713 · Cited by 62
Haerian, B. S., Lim, K. S., Tan, C. T., Raymond, A. A., & Mohamed, Z. (2011) · Pharmacogenomics · doi:10.2217/pgs.10.212 · Cited by 61
From molecules to medicines: the dawn of targeted therapies for genetic epilepsies
Demarest, S., & Brooks‐Kayal, A. R. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0099-3 · Cited by 60
From next-generation sequencing to targeted treatment of non-acquired epilepsies
Møller, R. S., Hammer, T. B., Rubboli, G., Lemke, J. R., & Johannesen, K. M. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1573144 · Cited by 60
Targeting microRNA-134 for seizure control and disease modification in epilepsy
Morris, G., Reschke, C. R., & Henshall, D. C. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.008 · Cited by 59
Löscher, W., & Brandt, C. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02183.x · Cited by 58
Self-citationLow potency and limited efficacy of antiepileptic drugs in the mouse 6 Hz corneal kindling model
Leclercq, K., Matagne, A., & Kaminski, R. M. (2014) · Epilepsy Research · doi:10.1016/j.eplepsyres.2014.02.013 · Cited by 58
Clinical studies and anti‐inflammatory mechanisms of treatments
French, J. A., Koepp, M. J., Naegelin, Y., Vigevano, F., Auvin, S., Rho, J. M., Rosenberg, E. C., Devinsky, O., Olofsson, P. S., & Dichter, M. A. (2017) · Epilepsia · doi:10.1111/epi.13779 · Cited by 58
Role of Blood-Brain Barrier Dysfunction in Epileptogenesis
Friedman, A., & Heinemann, U. (2012) · Oxford University Press eBooks · doi:10.1093/med/9780199746545.003.0027 · Cited by 55
Neuroinflammation imaging markers for epileptogenesis
Koepp, M. J., Årstad, E., Bankstahl, J. P., Dedeurwaerdere, S., Friedman, A., Potschka, H., Ravizza, T., Theodore, W. H., & Baram, T. Z. (2017) · Epilepsia · doi:10.1111/epi.13778 · Cited by 55
Self-citationReprogramming patient-derived cells to study the epilepsies
Parent, J. M., & Anderson, S. A. (2015) · Nature Neuroscience · doi:10.1038/nn.3944 · Cited by 54
In vivo P-glycoprotein function before and after epilepsy surgery
Bauer, M., Karch, R., Zeitlinger, M. A., Liu, J. Y. W., Koepp, M. J., Asselin, M., Sisodiya, S. M., Hainfellner, J. A., Wadsak, W., Mitterhauser, M., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000858 · Cited by 54
Self-citationResistance to Phenobarbital Extends to Phenytoin in a Rat Model of Temporal Lobe Epilepsy
Bethmann, K., Brandt, C., & Löscher, W. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.00980.x · Cited by 53
Self-citationJyonouchi, H., & Geng, L. (2016) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000456 · Cited by 53
Cited by
Löscher, W., & Klein, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00827-8 · Cited by 367
Self-citationPerucca, E., Perucca, P., White, H. S., & Wirrell, E. C. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00151-5 · Cited by 305
Astrocytes in the initiation and progression of epilepsy
Vezzani, A., Ravizza, T., Bedner, P., Aronica, E., Steinhäuser, C., & Boison, D. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00727-5 · Cited by 272
Self-citationThe Pharmacoresistant Epilepsy: An Overview on Existent and New Emerging Therapies
Fattorusso, A., Matricardi, S., Mencaroni, E., Dell'Isola, G. B., Di Cara, G., Striano, P., & Verrotti, A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.674483 · Cited by 269
Asadi-Pooya, A. A., Brigo, F., Lattanzi, S., & Blumcke, I. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01048-6 · Cited by 265
Metadata
- Authors
- Löscher, W., Potschka, H., Sisodiya, S. M., & Vezzani, A.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 72
- Issue
- 3
- Pages
- 606-638
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W3035511928
- Cited by
- 903
- References
- 238
- FWCI
- 58.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.